Witjes - Figure 44
Other immunotherapy in high-risk patients
Small trials done with other immunotherapies include one with recombinant adenovirus-mediated IFN-α2b (rAd-IFN-α2b) attached to an excipient, SCH 209702 (Syn 3), administered in 17 patients who had recurrences after BCG.[32] A total of 6 patients had complete responses at 3 months (35%), a promising response rate.
Gamma(γ)-irradiated mycobacteria have been tested in an attempt to avoid the installation infections associated with BCG, but unfortunately, although they produced an antitumor effect in vivo, the γ-irradiated mycobacteria were less effective than live mycobacteria.[33]
References
Dinney CP, Fisher MB, Navai N, et al. Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer. J Urol. 2013;190:850−6 http://dx.doi.org/10.1016/j.juro.2013.03.030
Noguera-Ortega E, Rabanal RM, Secanella-Fandos S, et al. γ irradiated mycobacteria enhance survival in bladder tumor bearing mice although less efficaciously than live mycobacteria. J Urol. 2016;195:198−205 http://dx.doi.org/10.1016/j.juro.2015.07.011
